Pfizer's stock soared following robust sales of COVID-19 products and key drugs, leading to stronger-than-expected earnings and an increased profit forecast for 2025.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Palantir Technologies soars with AI pivot, Pfizer holds steady, Caterpillar warns in contrasting earnings reports, offering investors a mix of optimism and caution in the tech, pharmaceutical, and ...

Pfizer has abanonded yet another GLP-1 drug from its shrinking obesity pipeline, as well as dumping a Clostridium difficile ...

Company rebuilding following decline in demand for its covid products, slashing about €6.2bn from its spending and focusing ...

Pfizer stock jumped early Tuesday after the drugmaker raised its earnings outlook on the back of a strong second-quarter ...

Pfizer reported a jump in second-quarter profits Tuesday behind higher sales of Covid-19 products and some other pharmaceuticals, while also benefiting from lower expenses.

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 a share to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the ...

Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter. The drugmaker now expects adjusted earnings per share between $2.90 and $3.10 compared ...

Palantir (NASDAQ: PLTR) stock climbed 5.9% after the data analytics and defense software group posted its biggest quarterly ...